Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa?
Saved in:
| Title: | Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa? |
|---|---|
| Alternate Title: | Macrolide-resistant Mycoplasma pneumoniae: Do we know the situation in Europe? |
| Authors: | Álvaro Varela, Ana Isabel1,2 ai.alvaro.varela@navarra.es, Aguinaga Pérez, Aitziber1,2, Navascués Ortega, Ana1,2, Castilla Catalán, Jesús2,3,4, Baquedano, Carmen Ezpeleta1,2 |
| Source: | Revista Española de Quimioterapia. jun2023, Vol. 36 Issue 3, p259-296. 38p. |
| Abstract (English): | Mycoplasma pneumoniae is a bacterium that lacks a cell wall. It produces infections all It produces infections worldwide, in epidemic outbreaks every 4-7 years, or endemically. Its clinical manifestations occur mostly in the respiratory tract and it is a common cause of atypical pneumonia. The treatment is with macrolides, tetracyclines or fluoroquinolones. Since 2000, an increase in resistance to macrolides has been detected worldwide, being more frequent in Asia. In Europe the frequency of resistance ranges between 1% and 25%, depending on the country. Molecular techniques and serology techniques provides very high sensitivity in diagnostic confirmation, being very useful for detecting and controlling M. pneumoniae outbreaks. The detection of resistance to macrolides requires a sequencing technique. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | Mycoplasma pneumoniae es una bacteria que carece de pared celular. Produce infecciones en todo el mundo, en brotes epidémicos cada 4-7 años, o en forma endémica. Sus manifestaciones clínicas se producen mayoritariamente en el tracto respiratorio y es una causa común de neumonía atípica. El tratamiento se realiza con macrólidos, tetraciclinas o fluoroquinolonas. Desde el año 2000 se ha detectado un aumento de resistencias a macrólidos a nivel mundial, siendo más frecuentes en Asia. En Europa la frecuencia de resistencias oscila entre el 1% y 25% en diferentes países. La combinación de técnicas moleculares y serológicas aporta una alta sensibilidad en la confirmación diagnóstica, siendo de gran utilidad para la detección y control de brotes de M. pneumoniae. La detección de resistencia a macrólidos requiere una técnica de secuenciación. [ABSTRACT FROM AUTHOR] |
| Copyright of Revista Española de Quimioterapia is the property of Sociedad Espanola de Quimioterapia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 163927160 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa? – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: Macrolide-resistant Mycoplasma pneumoniae: Do we know the situation in Europe? – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Álvaro+Varela%2C+Ana+Isabel%22">Álvaro Varela, Ana Isabel</searchLink><relatesTo>1,2</relatesTo><i> ai.alvaro.varela@navarra.es</i><br /><searchLink fieldCode="AR" term="%22Aguinaga+Pérez%2C+Aitziber%22">Aguinaga Pérez, Aitziber</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Navascués+Ortega%2C+Ana%22">Navascués Ortega, Ana</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Castilla+Catalán%2C+Jesús%22">Castilla Catalán, Jesús</searchLink><relatesTo>2,3,4</relatesTo><br /><searchLink fieldCode="AR" term="%22Baquedano%2C+Carmen+Ezpeleta%22">Baquedano, Carmen Ezpeleta</searchLink><relatesTo>1,2</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Revista+Española+de+Quimioterapia%22">Revista Española de Quimioterapia</searchLink>. jun2023, Vol. 36 Issue 3, p259-296. 38p. – Name: Abstract Label: Abstract (English) Group: Ab Data: Mycoplasma pneumoniae is a bacterium that lacks a cell wall. It produces infections all It produces infections worldwide, in epidemic outbreaks every 4-7 years, or endemically. Its clinical manifestations occur mostly in the respiratory tract and it is a common cause of atypical pneumonia. The treatment is with macrolides, tetracyclines or fluoroquinolones. Since 2000, an increase in resistance to macrolides has been detected worldwide, being more frequent in Asia. In Europe the frequency of resistance ranges between 1% and 25%, depending on the country. Molecular techniques and serology techniques provides very high sensitivity in diagnostic confirmation, being very useful for detecting and controlling M. pneumoniae outbreaks. The detection of resistance to macrolides requires a sequencing technique. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Spanish) Group: Ab Data: Mycoplasma pneumoniae es una bacteria que carece de pared celular. Produce infecciones en todo el mundo, en brotes epidémicos cada 4-7 años, o en forma endémica. Sus manifestaciones clínicas se producen mayoritariamente en el tracto respiratorio y es una causa común de neumonía atípica. El tratamiento se realiza con macrólidos, tetraciclinas o fluoroquinolonas. Desde el año 2000 se ha detectado un aumento de resistencias a macrólidos a nivel mundial, siendo más frecuentes en Asia. En Europa la frecuencia de resistencias oscila entre el 1% y 25% en diferentes países. La combinación de técnicas moleculares y serológicas aporta una alta sensibilidad en la confirmación diagnóstica, siendo de gran utilidad para la detección y control de brotes de M. pneumoniae. La detección de resistencia a macrólidos requiere una técnica de secuenciación. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Revista Española de Quimioterapia is the property of Sociedad Espanola de Quimioterapia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=163927160 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.37201/req/118.2022 Languages: – Code: spa Text: Spanish PhysicalDescription: Pagination: PageCount: 38 StartPage: 259 Titles: – TitleFull: Mycoplasma pneumoniae y resistencias a macrólidos: ¿Conocemos la situación en Europa? Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Álvaro Varela, Ana Isabel – PersonEntity: Name: NameFull: Aguinaga Pérez, Aitziber – PersonEntity: Name: NameFull: Navascués Ortega, Ana – PersonEntity: Name: NameFull: Castilla Catalán, Jesús – PersonEntity: Name: NameFull: Baquedano, Carmen Ezpeleta IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: jun2023 Type: published Y: 2023 Identifiers: – Type: issn-print Value: 02143429 Numbering: – Type: volume Value: 36 – Type: issue Value: 3 Titles: – TitleFull: Revista Española de Quimioterapia Type: main |
| ResultId | 1 |
